Impax Laboratories Inc.’s Oct. 9 purchase of several interrelated, privately held pharmaceutical companies should bring new options to a company dealing with manufacturing woes, bringing it a new manufacturing facility as well as marketed products and a suite of generic products and pipeline candidates.
Based in Hayward, Calif., Impax had been awaiting an FDA decision by Oct. 9 on an NDA for its Parkinson’s...